| Treating breast cancer in the 21st century: emerging biological therapies G Tinoco, S Warsch, S Glück, K Avancha, AJ Montero Journal of Cancer 4 (2), 117, 2013 | 219 | 2013 |
| Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma … L Li, AC Paz, BA Wilky, B Johnson, K Galoian, A Rosenberg, G Hu, ... PloS one 10 (9), e0133813, 2015 | 122 | 2015 |
| Impact of a venous thromboembolism prophylaxis “smart order set”: improved compliance, fewer events AM Zeidan, MB Streiff, BD Lau, SR Ahmed, PS Kraus, DB Hobson, ... American journal of hematology 88 (7), 545-549, 2013 | 108 | 2013 |
| Nirogacestat, a γ-secretase inhibitor for desmoid tumors M Gounder, R Ratan, T Alcindor, P Schöffski, WT Van Der Graaf, BA Wilky, ... New England Journal of Medicine 388 (10), 898-912, 2023 | 75 | 2023 |
| Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications D Spakowicz, R Hoyd, M Muniak, M Husain, JS Bassett, L Wang, ... BMC cancer 20, 1-13, 2020 | 52 | 2020 |
| Association of combination of conformation-specific KIT inhibitors with clinical benefit in patients with refractory gastrointestinal stromal tumors: a phase 1b/2a … AJ Wagner, PL Severson, AF Shields, A Patnaik, R Chugh, G Tinoco, ... JAMA oncology 7 (9), 1343-1350, 2021 | 25 | 2021 |
| SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma. YM Mowery, KV Ballman, RF Riedel, BE Brigman, S Attia, CF Meyer, ... Journal of clinical oncology 36 (15_suppl), TPS11588-TPS11588, 2018 | 20 | 2018 |
| Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis D Quiroga, DA Liebner, JS Philippon, S Hoffman, Y Tan, JL Chen, ... BMC cancer 20, 1-11, 2020 | 18 | 2020 |
| Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival TC Haddad, S Zhao, M Li, SH Patel, A Johns, M Grogan, G Lopez, A Miah, ... Cancer Immunology, Immunotherapy, 1-9, 2022 | 16 | 2022 |
| The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase. G Tinoco, BA Wilky, A Paz-Mejia, A Rosenberg, JC Trent American Society of Clinical Oncology educational book/ASCO. American …, 2015 | 16 | 2015 |
| Cardio-oncology: cancer therapy-related cardiovascular complications in a molecular targeted era: new concepts and perspectives D Hurtado-de-Mendoza, A Loaiza-Bonilla, PA Bonilla-Reyes, G Tinoco, ... Cureus 9 (5), 2017 | 15 | 2017 |
| Estado del arte: Utilidad de la inmovilización cervical en trauma CJ Madiedo, GRT Suárez, JRN Vargas Revista Colombiana de Anestesiología 32 (1), 43-53, 2004 | 13 | 2004 |
| Cancer and aging handbook K Bellizzi, M Gosney Wiley-Blackwell, 2012 | 12 | 2012 |
| Prospective evaluation of the concordance of commercial circulating tumor DNA alterations with tumor-based sequencing across multiple soft tissue sarcoma subtypes B Demoret, J Gregg, DA Liebner, G Tinoco, S Lenobel, JL Chen Cancers 11 (12), 1829, 2019 | 11 | 2019 |
| A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in … AJ Wagner, WD Tap, AF Shields, A Patnaik, R Chugh, G Tinoco, ... Journal of clinical oncology 36 (15_suppl), 11509-11509, 2018 | 11 | 2018 |
| Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival A Miah, G Tinoco, S Zhao, L Wei, A Johns, S Patel, M Li, M Grogan, ... Journal of Cancer Research and Clinical Oncology 149 (5), 2235-2242, 2023 | 8 | 2023 |
| Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy. M Husain, M Xu, S Patel, A Johns, M Grogan, M Li, G Lopez, A Miah, ... Journal of Clinical Oncology 39 (15_suppl), 2633-2633, 2021 | 8 | 2021 |
| A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib N Alavi, V Florou, G Tinoco, JC Trent, BA Wilky Discovery medicine 25 (137), 131-144, 2018 | 8 | 2018 |
| Metastatic sporadic paraganglioma with EWSR1:: CREM gene fusion: A unique molecular profile that expands the phenotypic diversity of the molecular landscape of the EWSR1:: CREM … S Javaid, A Patton, G Tinoco, S Oghumu, OH Iwenofu Genes, Chromosomes and Cancer 62 (2), 85-92, 2023 | 7 | 2023 |
| Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy D Spakowicz, R Hoyd, M Husain, G Tinoco, SH Patel, JT Burkart, ... age (mean (sd) 62, 13.26, 2019 | 7 | 2019 |
David A. Liebner, MDAssistant Professor of Internal Medicine and Biomedical Informatics, the Ohio State UniversityBestätigte E-Mail-Adresse bei osumc.edu
